ÂÜÀòÂÒÂ×

Erik Doevendans has 25 years’ industry experience with expertise in drug development and a background in regulatory affairs, quality assurance and manufacturing operations. He served as senior director Regulatory Affairs and manufacturing at Pharming NV where he brought recombinant C1-inhibitor to the market. Notably he was previously a senior pharmaceutical assessor at the Dutch regulatory authorities and an expert to the European Medicines Agency (EMA). Erik has an MSc in Pharmacy from Utrecht University, where he is still involved in the department of Pharmaceutics, with special interest in regulatory science and the relevancy of animal models used in non-clinical development.